10
Participants
Start Date
January 22, 2021
Primary Completion Date
March 26, 2021
Study Completion Date
March 26, 2021
siCoV/KK46
"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
NRC Institute of Immunology FMBA, Moscow
St. Petersburg Research Institute of Vaccines and Sera
OTHER_GOV
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
OTHER